|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers. |
| 公司地址
| 2269 Chestnut Street, No. 523, San Francisco, CA, USA, 94123 |
| 電話號碼
| +1 415 851-0195 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.forhims.com |
| 員工數量
| 2442 |
| Mr. Andrew Dudum |
Chief Executive Officer and Chairman of the Board |
美元 494.79K |
28/04/2026 |
| Ms. Soleil Boughton |
Chief Legal Officer and Corporate Secretary |
美元 464.38K |
28/04/2026 |
| Ms. Irene Becklund |
Chief Accounting Officer |
-- |
17/07/2026 |
| Ms. Deborah M. Autor |
Chief Policy Officer and Director |
-- |
28/04/2026 |
| Mr. Oluyemi Okupe |
Chief Financial Officer |
美元 530.88K |
28/04/2026 |
| Mr. Michael Chi |
Chief Operating Officer |
美元 485.00K |
28/04/2026 |
| Mr. Mohamed Elshenawy |
Chief Technology Officer |
美元 375.00K |
28/04/2026 |
|
|
| Mr. Kare Schultz |
Independent Director |
28/04/2026 |
| Mr. David Bolling Wells |
Lead Independent Director |
28/04/2026 |
| Mr. Christopher D. Payne |
Independent Director |
28/04/2026 |
| Ms. Anja L. Manuel |
Independent Director |
28/04/2026 |
| Mr. Kofi Amoo-Gottfried |
Independent Director |
15/06/2026 |
| Mr. Andrew Dudum |
Chief Executive Officer and Chairman of the Board |
28/04/2026 |
| Dr. Delos M. Cosgrove, M.D. |
Independent Director |
28/04/2026 |
| Ms. Andrea G. Perez Garcia |
Independent Director |
28/04/2026 |
| Ms. Deborah M. Autor |
Chief Policy Officer and Director |
28/04/2026 |
|
|
|
|
